The metabolism of acyclovir to its mono-, di-, and triphosphate derivatives was examined in uninfected and virus-infected cells. The level of phosphorylation of acyclovir was dependent upon virus type, cell line, exogenous drug concentration, and exposure time. Acyclovir phosphorylation was inhibited by exogenously added nucleosides. The order of inhibition was deoxythymidine > deoxycytidine > guanosine -deoxyguanosine. Acyclovir triphosphate persisted in infected cells after removal of the drug from the medium. The initial half-life of the triphosphate was 1.2 h in the absence of the drug in the medium, but triphosphate levels reached a plateau after 6 h. The presence of low concentrations of the drug in the medium resulted in a longer persistence of the intracellular triphosphate and a higher plateau level.
vir) is a derivative of guanine with an acyclic side chain, which selectively inhibits the replication of herpes simplex virus types 1 and 2 (HSV-1 and HSV-2) (5, 11, 14) . Preliminary in vitro studies (8) showed that acyclovir is converted to the mono-, di-, and triphosphorylated forms in cells infected with HSV-1. The initial phosphorylation of acyclovir to the monophosphate (acyclo-GMP) is catalyzed by the HSV-1-induced thymidine kinase (8, 12) . Subsequent phosphorylation to the di-and triphosphate forms is carried out by cellular enzymes (10, 13) . In the uninfected cell, these phosphorylations occur to a very limited degree. The end product of the phosphorylation of acyclovir, the triphosphate (acyclo-GTP), acts as a competitive inhibitor of, and an alternate substrate for, the virusinduced deoxyribonucleic acid (DNA) polymerase (8, 10, 15) .
In a continuation of these studies, to elucidate the mechanism by which acyclovir exerts its antiviral activity, the metabolism of acyclovir in uninfected and virus-infected cells has been investigated in greater detail.
MATERIALS AND METHODS Cells. African green monkey kidney (Vero) cells and human embryo fibroblast (WI38) cells were obtained from the American Type Culture Collection (ATCC), Rockville, Md. L929 cells were obtained from N. Cohn of these laboratories. Mycoplasmas were not detected in cell cultures by electron microscopic examination. Cells were grown in Eagle modified minimal essential medium as described (8, 15 figure legends) . After incubation at 37°C for the times indicated in the legends, the cells were removed from the surface of each roller bottle by brief trypsinization (0.25% trypsin and 0.02% ethylenediaminetetraacetic acid). The cells were then washed three times with ice-cold phosphatebuffered saline (pH 7.4). Nucleotide extracts were prepared with 10 ml of cold 3.5% perchloric acid (8) .
Sodium inosine triphosphate was included in the extraction as a recovery standard. To ascertain whether there was any loss of nucleotides from the cells during the trypsinization and washing procedure, the trypsin and buffer washes were collected and analyzed. This method of harvesting cells resulted in a loss of only 6% of the extractable ribonucleotides, and no loss of acyclovir nucleotides was detected.
Nucleotide analysis. (Fig. 2) . At 2 h postinfection acvclovir nucleotides were detectable. Acyclo-GMP, -GDP, and -GTP levels were highest at 8 h postinfection. GTP but appeared to elevate acyclo-GMP levels (Table 3) .
Persistence of acyclo-GTP in infected cells. The (Fig. 3) , with slower release thereafter. Approximately 6 h after drug removal, the amount of ["C]acyclovir released into the medium had plateaued at a concentration of 3.1 pM (Fig. 4) . The 3) . A plateau was reached at 6 h in the presence of 1 uM concentration of the drug and at 4 h in the presence of 10 pM acyclovir. DISCUSSION The potent and selective antiherpetic activity of acyclovir is due to its conversion to the monophosphate by the virus-specified thymidine kinase (8, 12) , followed by phosphorylation to the triphosphate by cellular enzymes and the sub- sequent inhibition of the herpes-specified DNA polymerase by the triphosphate (8, 11) . The studies described here extend those of Elion et al. (8) and show that the extent of acyclovir triphosphate formation is dependent upon the virus, cell type, exogenous drug concentration, time of exposure to acyclovir, and the presence of other nucleosides in the surrounding medium. The concentration of 100 1iM acyclovir was selected for most incubations in this study to demonstrate that even at this relatively high drug concentration, there was little anabolism to the triphosphate in uninfected cells. For the purpose of comparison, this same concentration was used in infected cells. However, in other studies done in this laboratory, acyclovir concentrations as low as 0.5 1iM were used to demonstrate the selective phosphorylation of the drug to the triphosphate in HSV-infected cells (8, 15) .
Infection of cells with HSV-1 or -2 resulted in the production of high levels of acyclovir nucleotides compared to those formed in uninfected cells. Little phosphorylation of acyclovir was found to occur in uninfected cells. Uninfected mouse L929 cells formed more acyclovir triphosphate (Table 2) than Vero or W138 cells (Table  1) and were more susceptible to inhibition by acyclovir (ED50 = 50 ,uM) than Vero (ED50 = 300 MM) (7) or W138 cells (ED5) > 3,000 ttM) (14) . 6) .
Differences in acyclovir nucleotide levels in cells infected with different viruses are apparently due to differences in the amount and in the nature of the virus-coded thymidine kinase. Vaccinia virus, which induces a virus-specified thymidine kinase, is not susceptible to acyclovir and is unable to phosphorylate acyclovir significantly (12) . Since the levels of acyclo-GTP do not approach the apparent Ki for the vaccinia virus-specified DNA polymerase, it is not surprising, then, that the virus is not susceptible to inhibition by acyclovir (15). Herpesviruses, such as HCMV, which do not code for a thymidine kinase (9) , also are unable to appreciably phosphorylate acyclovir and are not susceptible to inhibition by acyclovir except at high concentrations where the amount of triphosphate formed approaches the relatively low Ki value for the HCMV DNA polymerase (15). HSV-1-infected cells produced large quantities of acyclo-GTP. HSV-2 infected cells, however, produced even larger quantities of acyclo-GTP compared to cells infected with HSV-1. These differences may be due to qualitative differences in the thymidine kinases of HSV-1 and HSV-2 or to a greater quantity of HSV-2 thymidine kinase induced compared with the amount induced by HSV-1 (2).
Acyclovir levels are higher in infected cells than in uninfected cells. This may be due to facilitated transport involving the viral thymidine kinase (1, 10) or permeability changes in the membrane of virally infected cells or both. The time at which peak levels of drug are attained, especially the triphosphate form (the active form of the drug) is at 8 h postinfection. After this time the amount of triphosphate decreases, presumably due to degradation (3) and leakage of drug from the infected cells. The decline in triphosphate levels after 8 h postinfection would not be expected to affect antiviral activity because sufficiently high levels of acyclo-GTP for inhibition of the viral DNA polymerase persist and because the time when acyclovir is most effective at inhibiting virus replication is during the first 8 h of the infectious cycle (5 (12, 13) . Deoxythymidine and deoxycytidine inhibit the formation of the mono-, di-, and triphosphate forms of acyclovir. These nucleosides presumably compete with acyclovir at the level of the virus thymidine kinase, so that the phosphorylation of acyclovir to the monophosphate is inhibited. Consequently, concentrations of the di-and triphosphate forms are lower. Deoxyguanosine and guanosine probably compete at the level of the host cell guanylate kinase (the enzyme responsible for converting the monophosphate to the diphosphate), thereby inhibiting acyclo-GDP formation. The inhibition of acyclo-GDP formation in turn leads to the lower concentration of acyclo-GTP and to the apparent accumulation of acyclo-GMP levels.
After removal of acyclovir (100 tM) from the medium, half of the acyclo-GTP present in infected cells before drug removal was still present 1.2 h later. After an initial decline, the intracellular concentration of acyclo-GTP leveled off and persisted for 4 to 6 h at a concentration approximately 20 to 38 times the apparent Ki for the viral DNA polymerase (8, 11) . The presence of low concentrations (1 and 10 jiM) of acyclovir in the medium prolonged the half-life of acyclo-GTP and increased the concentration at which acyclo-GTP plateaued. These in vitro studies suggest that in vivo, where the half-life of acyclovir in human plasma is 2.1 to 3.8 h (7), the half-life in infected cells may be quite different. Inhibitory levels of acyclo-GTP may persist in the infected cells of a host even after acyclovir in the plasma is no longer detectable. The persistence of low concentrations of drug in the plasma would be expected to maintain a higher level of acyclo-GTP in the infected cells than would be present if all of the drug were removed from the plasma. This may extend the effectiveness of the acyclovir beyond the time indicated by its plasma half-life.
